Abstracts Archive - Page 612 of 2607 - ACR Meeting Abstracts

Abstract Number: 1945 • ACR Convergence 2022
Determinants of Patient’s Global Assessment of Disease Severity and Predictors of Disease Course in Juvenile Fibromyalgia
Clara Malattia¹, Claudio Lavarello¹, Alessandra Alongi², Benedetta Mori², Anna Ronchetti³, Lino Nobili⁴, Lorenzo Chiarella⁵, Elena Pescio⁶, Angelo Ravelli⁷ and Marco Gattorno⁸, ¹Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy,Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Genova, Italy, ²Department of Pediatric Emergency, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy, ³Physical Medicine and Rehabilitation Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁴Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy,Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Genova, Italy, ⁵Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy,Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Genova, ⁶Psychology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁷Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Italy,Scientific Direction, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁸Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Juvenile Fibromyalgia Syndrome (JFS) is a disabling condition characterized by widespread musculoskeletal pain, fatigue and mood disturbances, which impact significantly on patients' quality of…
Abstract Number: 1942 • ACR Convergence 2022
Maybe Silent: Spine Disease in Chronic Recurrent Multifocal Osteomyelitis, Clinical Features, Risk Factors, and Red Flags
Shima Yasin¹, T. Shawn Sato², Emma Leisinger², Aleksander Lenert², Yongdong (Dan) Zhao³ and Polly Ferguson¹, ¹University of Iowa Carver College of Medicine, Iowa City, IA, ²University of Iowa, Iowa City, IA, ³University of Washington, Redmond, WA
Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is a female predominant autoinflammatory bone disease. The average age at disease onset is 9-10 years. The majority have…
Abstract Number: 1934 • ACR Convergence 2022
Transition Readiness Before versus After Adolescents with Rheumatic Disease Transition to Adult Care
Christina Ma¹, Alessana Carmona², Habeba Talaat², Julie Herrington³, Tania Cellucci⁴, Stephanie Garner², Mark Matsos², KAREN BEATTIE² and Michelle Batthish², ¹McMaster University, Canada, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³ACPAC, Hamilton, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased disease activity and morbidity for patients with rheumatic disease. Consequently, there has…
Abstract Number: 1941 • ACR Convergence 2022
Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents
Melissa Argraves¹, Melissa Lerman¹, Julie Chase² and Samuel Goldfarb³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Kentucky, Lexington, KY, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Idiopathic Pulmonary Hemosiderosis (IPH) is a rare, pediatric predominant condition causing episodic diffuse alveolar hemorrhage, which can be recurrent and life-threatening. Chronic steroid use…
Abstract Number: 1952 • ACR Convergence 2022
Burden of Disease in Refractory Rheumatoid Arthritis
Kristin Wipfler¹, Bobby Kwanghoon Han², Urbano Sbarigia³, Federico Zazzetti⁴, Anna Sheahan⁵, Iris Lin⁶, Patricia Katz⁷, Evo Alemao⁸ and Kaleb Michaud⁹, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Johnson & Johnson, Beerse, Belgium, ⁴Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁵Janssen Research and Development, Chapel Hill, NC, ⁶Janssen, Horsham, PA, ⁷UCSF, San Rafael, CA, ⁸Janssen, Princeton, NJ, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment and the improved outcomes that have been associated with the expanding number of advanced therapies available, a substantial…
Abstract Number: 1948 • ACR Convergence 2022
Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Hyun Ho Lee¹, Lauren Blazek² and Eveline Wu³, ¹The University of North Carolina Chapel Hill, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, NC
Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase…
Abstract Number: 1950 • ACR Convergence 2022
Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Ryan Lennon³, John Davis³ and Elena Myasoedova³, ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for serious infections. Several infection risk scores have been developed over the last decade for…
Abstract Number: 1946 • ACR Convergence 2022
Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile
Jonathan Li¹, Emily Mirizio², Katherine Buhler³, Anne Stevens⁴, May Choi⁵, Kaila Schollaert-Fitch², Kathryn Torok², Christopher Liu² and Marvin Fritzler³, ¹Combined Internal Medicine-Pediatrics Residency Program, Children's Hospital of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ³University of Calgary, Calgary, AB, Canada, ⁴Janssen, Hansville, WA, ⁵Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Commercially available autoantibody (AAb) panels are developed for adult rheumatological diseases; application to pediatric disease has not been established. As a pediatric scleroderma referral…
Abstract Number: 1840 • ACR Convergence 2022
The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease Perform Lower Than Expected: Data from a Norwegian Cohort
Jens Vikse¹, Oyvind Midtvedt², Oyvind Molberg³, Bjørg Tilde Svanes Fevang⁴, Oyvind Palm², Torhild Garen², Katrine Brække Norheim⁵, Gunnstein Bakland⁶, Marianne Wallenius⁷ and Anna-Maria Hoffmann-Vold², ¹University of Bergen, Stavanger, Norway, ²Oslo University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Nepal, ⁴Haukeland University Hospital, Bergen, Norway, ⁵Stavanger University Hospital, Stavanger, Norway, ⁶University Hospital of North-Norway, Tromsø, Norway, ⁷St. Olav University Hospital, Trondheim, Norway
Background/Purpose: Milestones in the field of IgG4-related disease (IgG4-RD) include the 2011 Comprehensive Diagnostic Criteria (CDC), the 2019 ACR/EULAR classification criteria, and the recent identification…
Abstract Number: 1454 • ACR Convergence 2022
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
Sarah Reid¹, Johanna K Sandling¹, Pascal Pucholt¹, Ahmed Sayadi¹, Christopher Sjöwall², Karoline Lerang³, Andreas Jönsen⁴, Anders A Bengtsson⁴, Øyvind Molberg³, Anna Rudin⁵, Solbritt Rantapää-Dahlqvist⁶, Lars Ronnblom⁷ and Dag Leonard¹, ¹Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁶Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁷Uppsala University, Uppsala, Sweden
Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
Abstract Number: 1905 • ACR Convergence 2022
Does Exercise Before Surgery Predict Trajectories of Physical Activity After Knee Replacement?
Jéssica Bianca Aily¹, Dana Voinier¹, Jason Jakiela¹, Thomas Bye¹, Hiral Master¹, Louise Thoma² and Daniel White¹, ¹University of Delaware, Newark, DE, ²UNC School of Medicine, Chapel Hill, NC
Background/Purpose: Total knee replacement (TKR) is the definitive treatment for adults with knee osteoarthritis (OA) and is often successful in reducing pain and improving function.…
Abstract Number: 1451 • ACR Convergence 2022
Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE
Christina Stankey¹, Philip Chu², Alicia Hinze³, Lily McMorrow¹, Alia El-Qunni¹, Deepali Sen¹, Seth Eisen¹, Yo-El Ju¹ and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Duke University Hospital, Raleigh, NC, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Poor sleep quality is a common complaint of patients with SLE. Although chronic sleep disruption is known to drive circadian rhythm disorders, the effects…
Abstract Number: 1899 • ACR Convergence 2022
A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (OA-10) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Yusuf Yazici¹, Christopher Swearingen², Heli Ghandehari³, Victor Lopez⁴, ismail simsek⁵, Mark Fineman⁶, Sarah Kennedy⁷, Jeyanesh Tambiah⁸ and Timothy McAlindon⁹, ¹New York University School of Medicine, La Jolla, CA, ²Samumed LLC, San Diego, CA, ³Biosplice Therapeutics, Inc., San Diego, CA, ⁴Biosplice Therapeutics, Santa Clarita, CA, ⁵Alpine Immunesciences, San Diego, CA, ⁶Biosplice Therapeutics, San Diego, CA, ⁷Biosplice Therapeutics, Inc, San Diego, CA, ⁸Biosplice Ther Inc., San Diego, CA, ⁹Tufts Medical Center, Arlington, MA
Background/Purpose: Knee osteoarthritis (OA) is a common joint disorder associated with pain, disability, and joint damage. There remains a large unmet need for treatments that…
Abstract Number: 1947 • ACR Convergence 2022
Medication Use in Childhood Sjogren Disease
Erin Treemarcki¹, Matthew Basiaga², Scott Lieberman³ and Sara Stern¹, ¹University of Utah, Salt Lake City, UT, ²Mayo Clinic, Inver Grove Heights, MN, ³University of Iowa, Iowa City, IA
Background/Purpose: Childhood Sjogren’s Disease (childSD) is a rare complex chronic autoimmune disease primarily affecting lacrimal and salivary glands. Currently there is a paucity of information…
Abstract Number: 1958 • ACR Convergence 2022
The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
Sabine Dieperink¹, Bente Glintborg², Frank Mehnert³, Mette Nørgaard³, Louise Bruun Oestergaard⁴, Thomas Benfield⁵, Christian Torp-Pedersen⁶, Andreas Petersen⁷ and Merete Lund Hetland¹, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Rigshospitalet, Glostrup, Virum, Denmark, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark, ⁵Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Denmark, ⁶Copenhagen University Hospital - North Zealand, Copenhagen, Denmark, ⁷Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Staphylococcus aureus bacteremia (SAB) has high mortality.[1] We have previously identified an approximately doubled risk in patients with rheumatoid arthritis (RA),[2] but the role…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].